The impact of CYP2D6 mediated drug–drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine
Open Access
- 24 September 2018
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 84 (12), 2704-2715
- https://doi.org/10.1111/bcp.13741
Abstract
Aim Metoprolol (a CYP2D6 substrate) is often co‐prescribed with paroxetine/fluoxetine (a CYP2D6 inhibitor) because the clinical relevance of this drug–drug interaction (DDI) is still unclear. This review aimed to systematically evaluate the available evidence and quantify the clinical impact of the DDI. Method Pubmed, Web of Science, Cochrane Library and Embase were searched for studies reporting on the effect of the DDI among adults published until April 2018. Data on pharmacokinetics, pharmacodynamics and clinical outcomes from experimental, observational and case report studies were retrieved. The protocol of this study was registered in PROSPERO (CRD42018093087). Results We found nine eligible articles that consisted of four experimental and two observational studies as well as three case reports. Experimental studies reported that paroxetine increased the AUC of metoprolol three to five times, and significantly decreased systolic blood pressure and heart rate of patients. Case reports concerned bradycardia and atrioventricular block due to the DDI. Results from observational studies were conflicting. A cohort study indicated that the DDI was significantly associated with the incidence of early discontinuation of metoprolol as an indicator of the emergence of metoprolol‐related side effects. In a case–control study, the DDI was not significantly associated with bradycardia. Conclusion Despite the contradictory conclusions from the current literature, the majority of studies suggest that the DDI can lead to adverse clinical consequences. Since alternative antidepressants and beta‐blockers with comparable efficacy are available, such DDIs can be avoided. Nonetheless, if prescribing the combination is unavoidable, a dose adjustment or close monitoring of the metoprolol‐related side effects is necessary.Keywords
This publication has 58 references indexed in Scilit:
- Antidepressants, metoprolol and the risk of bradycardiaTherapeutic Advances in Psychopharmacology, 2011
- Influence of Metoprolol Dosage Release Formulation on the Pharmacokinetic Drug Interaction With ParoxetineThe Journal of Clinical Pharmacology, 2011
- Interaksjoner mellom metoprolol og antidepressive legemidlerTidsskrift for Den norske legeforening, 2011
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Meta‐analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non‐steroidal anti‐inflammatory drugsAlimentary Pharmacology & Therapeutics, 2007
- Antidepressant therapy in patients with ischemic heart diseaseAmerican Heart Journal, 2005
- Clinically Relevant Pharmacology of Selective Serotonin Reuptake InhibitorsClinical Pharmacokinetics, 1997
- Interaction of metoprolol and fluoxetineThe Lancet, 1993
- Oxidation Phenotype — A Major Determinant of Metoprolol Metabolism and ResponseNew England Journal of Medicine, 1982